Loading...
•
Dec 31, 2021
Orthofix Q4 2021 Earnings Report
Orthofix's financial performance was reported for Q4 2021, showing increased net sales and strategic advancements.
Key Takeaways
Orthofix reported a 6% increase in net sales for the fourth quarter of 2021, driven by double-digit growth in Global Spinal Implants and Orthopedics. Despite headwinds, the company delivered double-digit revenue growth and advanced strategic initiatives. The company anticipates accelerating top line growth in 2022 and beyond.
Net sales for the fourth quarter increased by 6% year-over-year to $125.1 million.
Double-digit net sales growth was achieved in both Global Spinal Implants and Orthopedics compared to the prior year period.
EPS was $(1.65) and adjusted EPS was $0.27 for the fourth quarter.
The company entered into a partnership and investment with nView medical.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company expects net sales between $475.0 million and $490.0 million, adjusted EBITDA between $56.0 million and $61.0 million, and adjusted EPS between $0.58 and $0.73 for the year ended December 31, 2022.
Positive Outlook
- Net sales are expected to increase by 2% to 5% on a reported basis.
- Net sales are expected to increase by 3% to 6% on a constant currency basis.
Challenges Ahead
- Adjusted EBITDA is expected to decrease by 9% to 0%.
- Adjusted EPS is expected to decrease by 33% to 15%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income